Compared to Estimates, Johnson & Johnson (JNJ) Q1 Earnings: A Look at Key Metrics

Core Insights - Johnson & Johnson reported $21.89 billion in revenue for Q1 2025, a year-over-year increase of 2.4% and an EPS of $2.77, up from $2.71 a year ago, exceeding Zacks Consensus Estimates for both revenue and EPS [1] Financial Performance - Revenue of $21.89 billion surpassed the Zacks Consensus Estimate of $21.62 billion, resulting in a surprise of +1.26% [1] - EPS of $2.77 exceeded the consensus estimate of $2.57, delivering a surprise of +7.78% [1] Key Metrics - Organic Sales Growth was reported at 4.2%, higher than the estimated 3.4% [4] - Sales in Innovative Medicine for Oncology (CARVYKTI) reached $369 million, significantly above the estimate of $341.85 million, marking a year-over-year increase of +135% [4] - Sales in Innovative Medicine for Neuroscience (SPRAVATO) were $320 million, slightly above the estimate of $319.68 million, with a year-over-year increase of +42.2% [4] - Total MedTech sales were $8.02 billion, below the estimate of $8.14 billion, reflecting a +2.5% change year-over-year [4] - Sales in MedTech for Cardiovascular (ABIOMED) were $420 million, exceeding the estimate of $400.66 million, with a year-over-year increase of +13.2% [4] Stock Performance - Johnson & Johnson shares returned -5.2% over the past month, compared to the Zacks S&P 500 composite's -3.9% change, indicating potential underperformance in the near term with a Zacks Rank 4 (Sell) [3]